Outlook Therapeutics, Inc.

NASDAQ:OTLK

Biotechnology

Healthcare
$0.40 -5.76%

-$0.10 today

Market cap
$97.62M
Beta
0.98
P/E (TTM)
-2.1
EPS (TTM)
-$0.74
52W Low $0.16High $3.39

Volume 6.81M

Average 17.46M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$51.83M

FY 2025 · Annual

Investing Cash Flow

$0.00

FY 2025 · Annual

Financing Cash Flow

$44.98M

FY 2025 · Annual

-25.4% YoY

Cash Flow Statement

USD
Metric
FY 2021
Sep 2021
FY 2022
Sep 2022
FY 2023
Sep 2023
FY 2024
Sep 2024
FY 2025
Sep 2025
Net Income(53.16M)(66.05M)(58.98M)(75.37M)(62.42M)
Depreciation & Amortization262.14K204.69K44.19K113.86K117.05K
Deferred Income Tax498.49K0000
Stock-Based Compensation4.89M7.71M5.55M5.39M8.9M
Change in Working Capital(7.08M)(1.68M)4.75M(3.02M)4.86M
Accounts Receivables0000(1.49M)
Inventory0000(3.34M)
Accounts Payables(198.47K)1.3M3.08M1.39M1.67M
Other Working Capital(6.88M)(2.98M)1.67M(4.41M)8.02M
Other Non-Cash Items341.55K3.15M5.66M4.09M1.58T
Operating Cash Flow(54.25M)(56.67M)(42.97M)(68.79M)(51.83M)
Capital Expenditures0000(3)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment6.31M(2.32M)19.77M(4.27K)(3.04M)
Common Stock Issued46.3M62.31M30.02M60.33M48.03M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.59M(394.15K)(823.89K)044.98T
Financing Cash Flow56.19M59.59M48.97M60.33M44.98M
Effect of Forex Changes00000
Net Change in Cash1.94M2.92M6M(8.46M)(6.84M)
Free Cash Flow(54.25M)(56.67M)(42.97M)(68.79M)(51.83M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$62.4M
+ D&A$117.1K
+ Stock-Based Comp$8.9M
+ Deferred Tax$0
+ Working Capital$4.9M
+ Other Non-Cash$1.6T
= Operating Cash Flow-$51.8M
- Capex-$3
= Free Cash Flow-$51.8M

Analysis

FY2025 free cash flow is -$51.8M. FCF conversion is 83.0% of net income. Operating cash flow was -$51.8M, with capex of -$3. The largest bridge item is Other Non-Cash at $1.6T.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingOct 13, 2026
8-KCurrent reportSep 30, 2026
8-KCurrent reportSep 18, 2026
4Statement of changes in beneficial ownershipSep 2, 2026
3Initial statement of beneficial ownershipSep 2, 2026

Does OTLK generate free cash flow?

Outlook Therapeutics, Inc. (OTLK) generated -$51.83M of free cash flow in fiscal 2025.

How much operating cash flow does OTLK produce?

Operating cash flow was -$51.83M, before capital expenditures of $3.00.